Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Carbonic anhydrase inhibitors and activators and their use in therapy

Scozzafava, Andrea, Mastrolorenzo, Antonio, Supuran, Claudiu T·2006·Expert Opinion on Therapeutic Patents

Abstract

Among the 16 different α-carbonic anhydrase (CA, EC 4.2.1.1) isoforms isolated in mammals, 13 possess catalytic activity for the reversible hydration of carbon dioxide to bicarbonate. Some of them are cytosolic (CA I, CA II, CA III, CA VII, CA XIII), others are membrane-bound (CA IV, CA IX, CA XII, CA XIV and CA XV); CA VA and CA VB are mitochondrial and CA VI is secreted in saliva and milk. Representatives of the β – δ-CA family are highly abundant in fungi, yeasts, plants, diatoms, bacteria and archaea. These enzymes are very efficient catalysts playing crucial physiological/pathological roles related to acid–base homeostasis, secretion of electrolytes, transport of ions, biosynthetic reactions and tumourigenesis. Many of the catalytically active CAs present in humans are targets for the drug design. CA inhibitors of the sulfonamide, sulfamate or sulfamide type show applications as antiglaucoma, antiepileptic, antiobesity or antitumour agents and they target different isoforms involved in such processes (CA II and XII for the antiglaucoma action; CA VII and II for the antiepileptic one; CA VA and VB for the antiobesity activity and CA IX and XII for the antitumour effects, respectively). Various CAs present in pathogenic organisms (such as Plasmodium falciparum, Helicobacter pylori, Mycobacterium tuberculosis, Candida albicans, Cryptococcus neoformans etc.) also started to be investigated recently as drug targets. Activation of mammalian CAs by various classes of activators intensively studied may ultimately lead to the design of pharmacologically useful derivatives for the enhancement of synaptic efficacy, which may represent a conceptually new approach for the treatment of depression, Alzheimer’s disease, ageing and other conditions in which spatial learning and memory therapy must be enhanced. Important progress has been achieved in the drug design of CA inhibitors and activators both by synthesising novel classes of such agents, in the search of compounds with selectivity for various isozymes and also by resolving the X-ray crystal structure of adducts of different CA isoforms with inhibitors/activators with pharmacological applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/13543776.16.12.1627

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 178

Metadata

Authors
Scozzafava, A., Mastrolorenzo, A., & Supuran, C. T.
Venue
Expert Opinion on Therapeutic Patents
Published
2006-11-22
Volume
16
Issue
12
Pages
1627-1664
ISSN
  • 1354-3776 (ISSN-L)
  • 1744-7674
OpenAlex
W2153237991
Cited by
178
References
2
FWCI
7.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Carbonic anhydrase inhibitors and activators and their use in therapy. https://app.cochat.ai/papers/10.1517/13543776.16.12.1627
The paper
Scozzafava, A., Mastrolorenzo, A., & Supuran, C. T. (2006). Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.16.12.1627

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.